Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here:


Immunovia’s vision is to lead the way in bioinformatic-assisted diagnostics towards a future where all patients are diagnosed in time for effective treatment, better quality of life and significantly improved survival.

Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.


IMMray technology platform


Immunovia headquarters in Lund houses a state of the art facility for producing antibodies and printing microarrays for proteomics analysis using robotic systems and high-throughput processes.


Immunovia’s quality systems will meet the regulatory requirements for ISO 13485 and 15189.


Immunovia plans to deploy patient testing from accredited laboratories.


Healthcare Systems

If you are interested in partnering with us on our clinical trials or other joint offerings for your patients, please reach out at

Other Partners

We are interested in innovative research opportunities and collaborations that could impact early detection and early stage cancer. If you would like to work with us, please reach out at